Project Grant R01FD008167
Award Date 9/25/25
Completion Date 8/31/29
Dollars Obligated $3.2M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $456,414 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, with a performance period from Jun 1, 2025 to Apr 30, 2030. The grant supports a Phase 2 clinical trial to evaluate the efficacy of repeated intracranial doses of B7-H3 chimeric antigen receptor (CAR) T cells for children and young adults with diffuse intrinsic pontine glioma...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
- This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $624,000.00 to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to conduct "COMPREHENSIVE IN VIVO PHENOTYPING OF FUSION-DRIVEN PEDIATRIC RHABDOMYOSARCOMAS". This 2-year research project aims to advance the understanding and treatment of pediatric rhabdomyosarcoma, an aggressive form of soft tissue cancer, by investigating the...
- This federal Project Grant award of $109,076 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to the University of Miami for the project "IMMUNO-MODULATING DIFFUSE MIDLINE GLIOMA BY EPI-TRANSCRIPTOMIC REPROGRAMMING". The project aims to advance scientific understanding and develop new approaches for treating diffuse midline glioma, an aggressive type of brain cancer in children with a 5-year survival rate of only 10%. The award period runs...
- This Project Grant award of $443,354 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand and target the metabolic dependencies of pediatric brain tumors, specifically diffuse midline gliomas (DMGs) harboring the H3K27M mutation. The research aims to investigate how metabolic pathways such as the hexosamine biosynthetic pathway can be...
- This federal Project Grant award of $604,852.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to investigate the role of glial progenitor cells in the initiation and recurrence of medulloblastoma, the most common malignant childhood brain tumor. The research aims to advance the understanding of tumor heterogeneity,...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...
- The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
- This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...